And the US Army Medical Research Acquisition Activity W8IWXH-04-1-0474 to DSC.Sieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RRESEARCH ARTICLEOpen AccessClinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation studyAnieta M Sieuwerts1, Marleen Ansems2, Maxime P Look1, P
Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap
Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap
Ator of nuclear receptors, we explored its prognostic value in relation to estrogen-receptor-a (ESR1) and -b (ESR2) and evaluated its predictive value for response to tamoxifen treatment. Methods: DC-SCRIPT mRNA levels were measured by real-time PCR in 1,505 primary invasive breast cancers and associated with outcome (disease-free survival (DFS), metastasis-free survival (MFS) and overall survival
Nd multivariable analysis higher DC-SCRIPT levels were associated with a favorable outcome for both the entire cohort and patients with lymph node-negative (LNN) disease that did not receive adjuvant therapy (DFS, MFS and OS; all, P
Ed two models. Model 1 was constructed using variables with P
Ed two models. Model 1 was constructed using variables with P